TMT proteomikanalys av erytroblaster från friska donatorer och erytroblaster/ringsideroblaster från patienter med MDS-RS TMT proteomics of erythroblasts from healthy donors and erythroblasts/ring sideroblasts from MDS-RS patients 2023-118-1-1 https://doi.org/10.48723/f2xa-4005 Swedish National Data Service Svensk nationell datatjänst Landing page TMT proteomikanalys av erytroblaster från friska donatorer och erytroblaster/ringsideroblaster från patienter med MDS-RS TMT proteomics of erythroblasts from healthy donors and erythroblasts/ring sideroblasts from MDS-RS patients 2023-118-1-1 https://doi.org/10.48723/f2xa-4005 10.1158/0008-5472.CAN-23-3038 Moura, Pedro Luis Moura, Pedro Luis Hellström-Lindberg, Eva Hellström-Lindberg, Eva 19 0200 19 0200 21 0340 21 0340 2021-01404_VR 2021-01404_VR 2017.0359 2017.0359 Swedish National Data Service Svensk nationell datatjänst Landing page Myelodysplastic Syndromes Myelodysplastiskt syndrom This dataset consists of semi-quantitative 10-plex TMT proteomics analysis of FACS-separated bone marrow cells obtained from 3 healthy bone marrow donors and 3 MDS-RS patients. The objective of this data collection was to assess several parameters on how the bone marrow of MDS-RS patients differs from that of healthy donors. The samples included in this analyses were 3 samples of sorted GPA+ erythroblasts pooled from 5 healthy donors (2+2+1) and 3 samples of sorted GPA+ erythroblasts plus 3 samples of purified ring sideroblats from 3 MDS-RS patients. This dataset includes the raw mass spectra, QC and processed results. Processing: In short, FACS-separated samples were snap frozen in liquid nitrogen. Cell pellets were lysed with 4 % SDS lysis buffer and prepared for mass spectrometry using a modified version of the SP3 protein clean up and digestion protocol published by Moggridge S. et al 2018. The following files are included in the dataset: - Processed data and analysis.xlsx (2.63 MB) - Variable_list_Processed_data_and_analysis.xlsx (23 KB) - Readme for raw data .zip file.txt (562 bytes) - Readme for Processed data.xlsx file (1.07 KB) - 13553_STD_EAEHPM1_10_TMT10_HiRIEF_3-10pH_20210504_07.15.zip (7.68 GB) Syftet med denna datainsamling var att bedöma flera parametrar om hur benmärgen hos MDS-RS-patienter skiljer sig från den hos friska donatorer. Denna datauppsättning består av semikvantitativ 10-plex TMT-proteomikanalys av FACS-separerade benmärgsceller erhållna från 3 friska benmärgsdonatorer och 3 MDS-RS-patienter. Se den engelska beskrivningen för mer information. Datasetet består av följande: - Processed data and analysis.xlsx (2.63 MB) - Variable_list_Processed_data_and_analysis.xlsx (23 KB) - Readme for raw data .zip file.txt (562 bytes) - Readme for Processed data.xlsx file (1.07 KB) - 13553_STD_EAEHPM1_10_TMT10_HiRIEF_3-10pH_20210504_07.15.zip (7.68 GB) CellsCells CellerCeller Patients with Myelodysplastic neoplasms with ring sideroblasts (MDS-RS) and healthy donors Patienter med myelodysplastisk syndrom med ringsideroblaster (MDS-RS) samt friska donatorer Numeric Other Bone marrow (BM) and/or peripheral blood (PB) samples were collected from 36 MDS-RS and 3 MDS non-RS patients evaluated at Karolinska University Hospital, Huddinge, Sweden. Diagnostic procedures were performed according to the European LeukemiaNet recommendation and WHO classification for myeloid neoplasms. As the specific purpose was to dissect the pathobiology of SF3B1-mutant MDS-RS, all MDS-RS patients belonged to the SF3B1α category in the IPSS-M risk classification. RS presence was quantified according to standard clinical practice. Additional samples were collected from a total of 40 healthy normal bone marrow (NBM) donors for control purposes. Please note that a deidentified donor and experiment index is provided in the companion publication for this dataset, including clinical and mutational status. All source material was provided with written informed consent for research use, given in accordance with the Declaration of Helsinki. In this dataset, samples from 3 MDS-RS patients and 3 healthy donors are included.Bone marrow (BM) and/or peripheral blood (PB) samples were collected from 36 MDS-RS and 3 MDS non-RS patients evaluated at Karolinska University Hospital, Huddinge, Sweden. Diagnostic procedures were performed according to the European LeukemiaNet recommendation and WHO classification for myeloid neoplasms. As the specific purpose was to dissect the pathobiology of SF3B1-mutant MDS-RS, all MDS-RS patients belonged to the SF3B1α category in the IPSS-M risk classification. RS presence was quantified according to standard clinical practice. Additional samples were collected from a total of 40 healthy normal bone marrow (NBM) donors for control purposes. Please note that a deidentified donor and experiment index is provided in the companion publication for this dataset, including clinical and mutational status. All source material was provided with written informed consent for research use, given in accordance with the Declaration of Helsinki. In this dataset, samples from 3 MDS-RS patients and 3 healthy donors are included. Probability: Simple randomProbability: Simple random Sannolikhetsurval: obundet slumpmässigt urvalSannolikhetsurval: obundet slumpmässigt urval Non-probability: AvailabilityNon-probability: Availability Icke-sannolikhetsurval: tillgänglighetsurvalIcke-sannolikhetsurval: tillgänglighetsurval Mixed probability and non-probabilityMixed probability and non-probability Blandat sannolikhets- och icke-sannolikhetsurvalBlandat sannolikhets- och icke-sannolikhetsurval Access to data through SND. Access to data is restricted. Åtkomst till data via SND. Tillgång till data är begränsad. restrictedAccess Moura PL, Mortera Blanco T, Hofman IJ, Todisco G, Kretzschmar WW, Björklund AC, Creignou M, Hagemann-Jensen M, Ziegenhain C, Cabrerizo Granados D, Barbosa I, Walldin G, Jansson M, Ashley N, Mead AJ, Lundin V, Dimitriou M, Yoshizato T, Woll PS, Ogawa S, Sandberg R, Jacobsen SW, Hellström-Lindberg E. Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts. Cancer Res. 2023 Nov 3. doi: 10.1158/0008-5472.CAN-23-3038. Moura PL, Mortera Blanco T, Hofman IJ, Todisco G, Kretzschmar WW, Björklund AC, Creignou M, Hagemann-Jensen M, Ziegenhain C, Cabrerizo Granados D, Barbosa I, Walldin G, Jansson M, Ashley N, Mead AJ, Lundin V, Dimitriou M, Yoshizato T, Woll PS, Ogawa S, Sandberg R, Jacobsen SW, Hellström-Lindberg E. Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts. Cancer Res. 2023 Nov 3. doi: 10.1158/0008-5472.CAN-23-3038. 10.1158/0008-5472.CAN-23-3038 2023